INDV

Indivior Pharmaceuticals, Inc. - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Indivior Pharmaceuticals, Inc. is the leader in long-acting injectable treatments for opioid use disorder (OUD), primarily through its flagship product SUBLOCADE. During this quarter, the Company completed a U.S. Domestication (redomiciliation from the U.K. to Delaware) effective January 26, 2026. The Company operates as a single segment focused on buprenorphine-based prescription drugs.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 19% year-over-year, driven by a 33% increase in U.S. SUBLOCADE sales ($218 million vs. $163 million). Rest of World revenue remained flat at $45 million.
• Profitability: Operating income more than doubled to $137 million, aided by a 10% reduction in operating expenses and a 4 percentage point increase in gross margin.
• Debt Restructuring: The Company issued $500 million in 0.625% Convertible Senior Notes due 2031. Proceeds were used to fully repay a $333 million term loan, resulting in an $18 million loss on debt extinguishment.
• Share Repurchases: The Company initiated a $400 million share repurchase program, purchasing approximately 4 million shares for $125 million in Q1 2026.
• Cash Flow: Operating cash flow turned negative ($9 million used) compared to $75 million provided in Q1 2025, primarily due to $34 million in litigation settlement payments and timing of tax/operational payments.

Guidance, Outlook, and Risks

• Outlook: Management has entered "Phase II - Accelerate" of the Indivior Action Agenda to accelerate SUBLOCADE growth and cash flow. Capital expenditures for 2026 are expected to be $20–$30 million, primarily for a new manufacturing facility in Raleigh, NC.
• Pipeline Updates: The Company will not pursue Phase 3 development of INDV-6001 or advance INDV-2000 internally, leading to expected decreases in future R&D expenses.
• Liquidity: The Company maintains negative working capital ($111 million deficit) due to the timing of rebate payments versus collections. Management believes current cash, investments, and debt capacity are sufficient for the next 12 months.
• Legal Risks:
  • Opioid Litigation: A $55 million accrual remains for settlements with municipalities and tribes. Payments of $26 million were made in Q1 2026.
  • Dental MDL: Approximately 1,900 cases involving 25,000 plaintiffs alleging dental injury from SUBOXONE Film are pending. No loss estimate can be made at this time.
  • U.K. Shareholder Claims: Multiparty claims regarding alleged product-hopping remain pending with no loss estimate.

Investor Verification Checklist

• Rebate Timing: Verify the sustainability of cash flow given the negative operating cash flow and the heavy reliance on the timing of government rebate collections versus payments.
• Debt Covenants: Confirm the specific financial covenants attached to the new $500 million Convertible Notes and the impact of the $18 million extinguishment loss on future leverage ratios.
• Litigation Exposure: Monitor the status of the Dental MDL and remaining Opioid MDL cases, as the current $55 million accrual may not cover all potential liabilities.
• Share Repurchase Execution: Track the utilization of the remaining $275 million in the share repurchase program and its impact on liquidity.
• Product Mix: Assess the continued growth trajectory of SUBLOCADE versus the decline in sublingual product revenue (SUBOXONE Film).